CN106518977A - Preparation method of oxytocin [5-Asp] - Google Patents
Preparation method of oxytocin [5-Asp] Download PDFInfo
- Publication number
- CN106518977A CN106518977A CN201710002364.7A CN201710002364A CN106518977A CN 106518977 A CN106518977 A CN 106518977A CN 201710002364 A CN201710002364 A CN 201710002364A CN 106518977 A CN106518977 A CN 106518977A
- Authority
- CN
- China
- Prior art keywords
- asp
- oxytocin
- phase
- crude product
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a preparation method of oxytocin [5-Asp]. The preparation method includes following steps: adopting high-performance liquid reversed phase chromatography to sequentially perform reversed phase cyclizing, reversed phase purifying and reversed phase desalting on an oxytocin [5-Asp] precursor crude product solution, wherein a filler of the high-performance liquid reversed phase chromatography is silica gel C18, and an oxytocin [5-Asp] precursor crude product contains two free sulfhydryl groups. A reversed phase adsorption method is creatively applied for cyclizing, purifying and desalting, so that the problems of cyclizing, purifying and desalting are solved once for all, production process is optimized, and the preparation method is suitable for industrial continuous production.
Description
Technical field
The present invention relates to field of biological pharmacy.More particularly it relates to a kind of preparation side of oxytocin [5-Asp]
Method.
Background technology
Oxytocin, also known as oxytocins, English entitled Oxytocin, structural formula:
Molecular formula is:C43H66N12O12S2, molecular weight is 1007.2
Oxytocin be used for induced labor, hasten parturition, the uterine hemorrhage that postpartum and post-abortion cause because uterine atony or contracting abdomen are bad;
Understand placenta reserve function (oxytocins enrages test);Collunarium can promote milk ejection.Oxytocin energy indirect stimulation uterine smooth muscle is received
Contracting, simulates the effect of eutocous uterine contractile, causes cervical dilatation, uterus to the reaction of oxytocin in During Pregnancy by
It is cumulative to add, peak is reached when mature.Oxytocin can also pierce mammotropic smooth muscle contraction, contribute to milk and discharge from breast, but and
The galactosis amount of mammary gland is not increased.
For a medicine, a small amount of impurity contained therein is to cause the most important reason of medicine side effect, therefore right
The inspection of its purity is to ensure one of important foundation of drug safety validity, and the content of purity test, according to each medicine
Property and feature it is somewhat different, but be substantially intended to be related to respective " relevant material " and check research.Synthesis polypeptide it is relevant
Material is unstable essentially from the process contaminants in building-up process and due to polypeptide and the catabolite of generation, polymer etc. are miscellaneous
Matter, although the purifying process of synthesis polypeptide has had great progress at present, process contaminants are still the relevant material of synthesis polypeptide
Important sources, this mainly due to synthesis polypeptide some process contaminants (such as disappearance peptide, fracture peptide, oxidation peptide, disulfide bond hand over
Product for changing etc.) may be very approximate with the property of medicine itself, so as to cause certain difficulty to purifying.Research shows to close
Into in polypeptide, modal catabolite is deamidation product, oxidation product, hydrolysate.In the various amino acid of composition polypeptide
In, asparagine, glutamine and peptide chain C section acid amides are easy to deamidation reaction (especially in pH value rising and high temperature bar
Under part).
As in synthesis polypeptide, the property of some impurity with target product closely, hence sets up suitable method abundant
It is the great difficulty faced during the relevant material of synthetic polypeptide medicaments is studied to detect these impurity.
Country's oxytocin [5-Asp] protected oxytocin resin using synthesis in solid state mostly before this at present, then dry through cracking
It is dry to obtain oxytocin [5-Asp] precursor crude product (Cys-Tyr-Ile-Gln-Asp-Cys-Pro-Leu-Gly-NH2Trifluoroacetic acid
Salt), high dilution cyclisation, purifying turn the steps such as salt, finally give oxytocin [5-Asp].High dilution cyclisation is dense due to sample
Degree is dilute, bulky, very unfavorable for later-period purification.Also lack now a kind of effective polypeptide bulk drug of the preparation containing disulfide bond
The method of analog, therefore still in the urgent need to developing the new preparation method containing disulfide bond polypeptide.
The content of the invention
The technical problem to be solved is for the preparation technology for overcoming oxytocin in prior art [5-Asp]
It is complicated, yield is low, sample concentration is dilute, bulky defect, and provides a kind of preparation method of oxytocin [5-Asp].This
The preparation method of the oxytocin [5-Asp] of invention is with polypeptide crude product oxytocin [5-Asp] containing a pair of free sulfhydryl groups (- SH)
Precursor crude product is initiation material, through the cyclisation of high pressure liquid phase reverse-phase chromatography, purifying and desalting steps, prepares highly purified oxytocin
The method of [5-Asp].The polypeptide of the present invention is 1 critical impurities in oxytocin preparation process, therefore can be examined as oxytocin
The standard reference material of survey process, carries out qualitative and quantitative analysis to oxytocin and impurity, for the quality mark for improving oxytocin
Standard, control product quality are significant.
The present invention is to solve above-mentioned technical problem by the following technical programs:
The invention provides a kind of preparation method of oxytocin [5-Asp], which comprises the steps:It is anti-using efficient liquid phase
Oxytocin [5-Asp] precursor crude product solution is carried out anti-phase cyclisation, anti-phase purifying, anti-phase desalination by phase chromatography successively, you can;It is high
The filler of effect liquid phase RP chromatography is silica gel C18;
Described oxytocin [5-Asp] precursor crude product is the oxytocin containing two free sulfhydryl groups [5-Asp] precursor crude product;
Described oxytocin [5-Asp] is
Wherein, described oxytocin [5-Asp] precursor crude product is preferably dried system through cracking using solid-phase synthesis
Oxytocin [5-Asp] the precursor crude product for obtaining, HPLC purity are 60~90%;The knot of described oxytocin [5-Asp] precursor crude product
Structure formula is Cys-Tyr-Ile-Gln-Asp-Cys-Pro-Leu-Gly-NH2Trifluoroacetate.
Wherein, described oxytocin [5-Asp] precursor crude product solution is preferably oxytocin [5-Asp] precursor crude product and is dissolved in
Concentration of volume percent is the 5g/L solution that 5% acetonitrile solution is formed.
In the present invention, described anti-phase cyclisation, anti-phase purifying, anti-phase desalination are complete in the anti-phase elution process of a step
Into.
Wherein, described anti-phase cyclisation, anti-phase purifying, the condition of anti-phase desalination are preferably as follows:Mobile phase A 1 be pure water, A2
For the H of percent by volume 0.01~0.05% (preferably 0.02~0.03%)2O2PH is 7.5~9.0 NaOH aqueous solution,
Mobile phase B is acetonitrile, and mobile phase C is described oxytocin [5-Asp] precursor crude product solution, flow velocity be 80~110mL/min (compared with
It is good for 100mL/min), Detection wavelength is 220nm;
Condition according to following table carries out online loading, wash-out, and percentage is percent by volume;
Elution step | Elution time | Eluent |
1 | 0~10min | 100%C |
2 | 10~25min | 95%A1+5%B |
3 | 25.1~30min | 95%A2+5%B |
4 | 30.1~35 | 95%A1+5%B |
5 | 35~50min | 95%A1+5%B → 80%A1+20%B |
6 | 50~65min | 80%A1+20%B → 73%A1+27%B |
7 | 65~75min | 50%A1+50%B |
8 | 75~80min | 95%A1+5%B |
Collect the eluent that retention time is 50~65min and obtain oxytocin [5-Asp] solution.
Wherein, the filling condition of described efficient liquid phase RP chromatography is preferably as follows:Filler is Kromasil silica gel
C18, aperture 10nm, 10 μm of particle diameter.
Oxytocin [5-Asp] is a kind of peptide material, unstable in the basic conditions, degradable, especially strong alkali environment
Under, the de- concentration of integrated survey of the present invention alkali cleaning and time, to ensure to reduce the destruction and loss of sample in desalination processes.
Innovative point of the present invention be will cyclisation, purifying and one step of desalination is anti-phase obtains polypeptide sterling, before oxytocin [5-Asp]
In body crude product contain two free sulfhydryl groups, traditional handicraft cyclisation and purify substep carry out, and be cyclized it is bulky, increased pure
The difficulty of change, for cyclisation rapidly and efficiently and preparation technology, designs the more recent application of silica gel C18 fillers.Present invention innovation
Property used the cyclisation of reverse phase absorption method, purifying and desalination, disposably solves the problems, such as cyclisation, purify and desalination.
On the basis of common sense in the field is met, above-mentioned each optimum condition can be combined, and obtain final product each preferable reality of the present invention
Example.
Agents useful for same of the present invention and raw material are commercially available.
The present invention positive effect be:
(1) present invention is first adsorbed onto reduced form polypeptide crude product in fixing phase, using polypeptide using the method for online cyclisation
With the hydrophobic binding of reverse phase filler, the acid ion of neutral wash-out weak binding on a column, and using pH meta-alkalis containing H2O2's
Mobile phase is rinsed, and promotes two sulfydryls into disulfide bond, obtains target polypeptides crude product, and sample retains on a column.
(2) using online cyclisation, the sample of cyclisation avoids wash-out, can carry out gradient and wash after directly converting mobile phase the present invention
De- purifying, obtains final sterling, is adapted to continuous production.
(3) present invention has innovatively used reverse phase absorption cyclisation, purifying, desalination one-step method that polypeptide sterling, optimization is obtained
Production technology, is adapted to that industrialization is continuous to be produced.
Specific embodiment
The present invention is further illustrated below by the mode of embodiment, but does not therefore limit the present invention to described reality
Among applying a scope.The experimental technique of unreceipted actual conditions in the following example, conventionally and condition, or according to business
Product specification is selected.
In following embodiments, oxytocin [5-Asp] is
Embodiment 1 (HPLC methods detect oxytocin [5-Asp] precursor crude product and purifying midbody solution purity and quantitative)
Instrument:1200 high performance liquid chromatographs of Agilent
Splitter:Waters XBridge-C18,4.6 × 150mm, 5 μm
Mobile phase:A is 50% acetonitrile solution of percent by volume, and B is 0.02M KH2PO43.0 aqueous solution of pH, flow velocity is
1.0mL/min, Detection wavelength is 220nm, room temperature detection, and shown in gradient see the table below, percentage is percent by volume.
Elution step | Elution time | Eluent |
1 | 0~15min | 35%A+65%B |
2 | 15~25min | 35%A+65%B → 100%A |
3 | 25~28min | 100%A |
4 | 28.0~28.1min | 100%A → 35%A+65%B |
5 | 28.1~32min | 35%A+65%B |
Embodiment 2 (50mm internal diameter L&L4002 prepare post filling)
With Load&Lock dynamic axial compressions and static locking technology, filler is silica gel C18 (Kromasil C18),
Aperture 10nm, 10 μm of particle diameter fill column density 0.66g/mL, are filled to post bed pressure 133bar, using the filling of Varian chromatograms are
System, 325g dry powder fillers, after the stirring homogenate of 650mL isopropanols, are poured internal diameter 50mm L&L4002 into and prepare post, and compression ratio is 1.5:
1, carrier gas is N2, adjust nebulizer gas pressure oil pressure meter pressure is caused for 200bar, dynamic axial compression to post bed height 25.5cm, work
Post is prepared used by anti-phase cyclisation, anti-phase purifying and anti-phase desalination scheme.
The anti-phase cyclisation of embodiment 3 oxytocin [5-Asp] precursor crude material, anti-phase purifying and anti-phase desalination
Instrument:Varian SD-1 high pressure liquid phase preparation systems
Chromatographic column:2 self-chambering of embodiment prepares post 50 × 255mm of Load&Lock4002,10 μm of 10nm of C18
Oxytocin [5-Asp] precursor crude product is to be dried obtained oxytocin [5-Asp] through cracking using solid-phase synthesis
Precursor crude product, structural formula are Cys-Tyr-Ile-Gln-Asp-Cys-Pro-Leu-Gly-NH2Trifluoroacetate.
It is dense that oxytocin [5-Asp] precursor crude product solution is dissolved in percent by volume for above-mentioned oxytocin [5-Asp] precursor crude product
Spend the 5g/L solution of the acetonitrile solution formation for 5%.
Mobile phase A 1 is purified water, and A2 is the H of percent by volume 0.022O2PH is the 7.5 NaOH aqueous solution, and Mobile phase B is
Acetonitrile, mobile phase C are described oxytocin [5-Asp] precursor crude product solution, and determining its HPLC purity as described in Example 1 is
81.50%, retention time is 9.73min.
The anti-phase cyclisation of the present embodiment, anti-phase purifying and anti-phase desalination condition are as follows:Flow velocity 100mL/min, 220nm are examined
Survey, purifying gradient see the table below shown in, percentage is percent by volume.
Elution step | Elution time | Eluent |
1 | 0~10min | 100%C |
2 | 10~25min | 95%A1+5%B |
3 | 25.1~30min | 95%A2+5%B |
4 | 30.1~35 | 95%A1+5%B |
5 | 35~50min | 95%A1+5%B → 80%A1+20%B |
6 | 50~65min | 80%A1+20%B → 73%A1+27%B |
7 | 65~75min | 50%A1+50%B |
8 | 75~80min | 95%A1+5%B |
Collect the eluent that retention time is 50~65min and obtain oxytocin [5-Asp] solution, as described in Example 1
It is 99.61% to determine its HPLC purity, and retention time is 6.29min.
The anti-phase cyclisation of embodiment 4 oxytocin [5-Asp] precursor crude material, anti-phase purifying and anti-phase desalination
Instrument:Varian SD-1 high pressure liquid phase preparation systems
Chromatographic column:2 self-chambering of embodiment prepares post 50 × 255mm of Load&Lock4002,10 μm of 10nm of C18
Oxytocin [5-Asp] precursor crude product is to be dried obtained oxytocin [5-Asp] through cracking using solid-phase synthesis
Precursor crude product, structural formula are Cys-Tyr-Ile-Gln-Asp-Cys-Pro-Leu-Gly-NH2Trifluoroacetate.
It is dense that oxytocin [5-Asp] precursor crude product solution is dissolved in percent by volume for above-mentioned oxytocin [5-Asp] precursor crude product
Spend the 5g/L solution of the acetonitrile solution formation for 5%.
Mobile phase A 1 is purified water, and A2 is the H of percent by volume 0.032O2PH is the 9.0 NaOH aqueous solution, and Mobile phase B is
Acetonitrile, mobile phase C are described oxytocin [5-Asp] precursor crude product solution, and determining its HPLC purity as described in Example 1 is
81.50%, retention time is 9.73min.
The anti-phase cyclisation of the present embodiment, anti-phase purifying and anti-phase desalination condition are as follows:Flow velocity 100mL/min, 220nm are examined
Survey, purifying gradient see the table below shown in, percentage is percent by volume.
Elution step | Elution time | Eluent |
1 | 0~10min | 100%C |
2 | 10~25min | 95%A1+5%B |
3 | 25.1~30min | 95%A2+5%B |
4 | 30.1~35 | 95%A1+5%B |
5 | 35~50min | 95%A1+5%B → 80%A1+20%B |
6 | 50~65min | 80%A1+20%B → 73%A1+27%B |
7 | 65~75min | 50%A1+50%B |
8 | 75~80min | 95%A1+5%B |
Collect the eluent that retention time is 50~65min and obtain oxytocin [5-Asp] solution, as described in Example 1
It is 99.52% to determine its HPLC purity, and retention time is 6.30min.
Embodiment 5 (Mass Spectrometer Method of oxytocin [5-Asp])
Embodiment 3,4 is determined using waters micromass ZQ substances level Four bar electrospray ionization mass spectrum (ESI-MS) to obtain
Oxytocin [5-Asp] molecular mass peak [M+1]+Measured value 1009.25, leading ion fragment peak [M+2]2+Measured value
505.13, all meet theoretical value 1008.2.
Claims (9)
1. a kind of preparation method of oxytocin [5-Asp], which comprises the steps:Will contracting palace using efficient liquid phase RP chromatography
Plain [5-Asp] precursor crude product solution carries out anti-phase cyclisation, anti-phase purifying, anti-phase desalination successively, you can;Efficient liquid phase reverse-phase chromatography
The filler of method is silica gel C18;
Described oxytocin [5-Asp] precursor crude product is the oxytocin containing two free sulfhydryl groups [5-Asp] precursor crude product;
Described oxytocin [5-Asp] is
2. preparation method as claimed in claim 1, it is characterised in that described oxytocin [5-Asp] precursor crude product is employing
Solid-phase synthesis are dried obtained oxytocin [5-Asp] precursor crude product through cracking, and HPLC purity is 60~90%.
3. preparation method as claimed in claim 1, it is characterised in that the structure of described oxytocin [5-Asp] precursor crude product
Formula is Cys-Tyr-Ile-Gln-Asp-Cys-Pro-Leu-Gly-NH2Trifluoroacetate.
4. preparation method as claimed in claim 1, it is characterised in that described oxytocin [5-Asp] precursor crude product solution is
Oxytocin [5-Asp] precursor crude product is dissolved in the 5g/L solution that the acetonitrile solution that concentration of volume percent is 5% is formed.
5. preparation method as claimed in claim 1, it is characterised in that described anti-phase cyclisation, anti-phase purifying, anti-phase desalination are equal
It is to complete in the anti-phase elution process of a step.
6. preparation method as claimed in claim 1, it is characterised in that described anti-phase cyclisation, anti-phase purifying, anti-phase desalination
Condition is as follows:Mobile phase A 1 is pure water, and A2 is the H of percent by volume 0.01~0.05%2O2PH be 7.5~9.0 NaOH it is water-soluble
Liquid, Mobile phase B are acetonitrile, and mobile phase C is described oxytocin [5-Asp] precursor crude product solution, and flow velocity is 80~110mL/
Min, Detection wavelength are 220nm;
Condition according to following table carries out online loading, wash-out, and percentage is percent by volume;
Collect the eluent that retention time is 50~65min and obtain oxytocin [5-Asp] solution.
7. preparation method as claimed in claim 6, it is characterised in that described A2 is percent by volume 0.02~0.03%
H2O2PH is 7.5~9.0 NaOH aqueous solution.
8. preparation method as claimed in claim 6, it is characterised in that described flow velocity is 100mL/min.
9. preparation method as claimed in claim 1, it is characterised in that the filling condition of described efficient liquid phase RP chromatography
It is as follows:Filler be Kromasil silica gel C18, aperture 10nm, 10 μm of particle diameter.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710002364.7A CN106518977B (en) | 2017-01-03 | 2017-01-03 | Preparation method of oxytocin [5-Asp ] |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710002364.7A CN106518977B (en) | 2017-01-03 | 2017-01-03 | Preparation method of oxytocin [5-Asp ] |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106518977A true CN106518977A (en) | 2017-03-22 |
CN106518977B CN106518977B (en) | 2019-12-31 |
Family
ID=58336694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710002364.7A Active CN106518977B (en) | 2017-01-03 | 2017-01-03 | Preparation method of oxytocin [5-Asp ] |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106518977B (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110016072A (en) * | 2019-05-07 | 2019-07-16 | 上海上药第一生化药业有限公司 | A kind of refining methd of oxytocin |
CN110028556A (en) * | 2019-05-07 | 2019-07-19 | 上海上药第一生化药业有限公司 | A kind of refining methd of oxytocin [- NH2] impurity |
CN110041406A (en) * | 2019-05-07 | 2019-07-23 | 上海上药第一生化药业有限公司 | A kind of refining methd of oxytocin [+Gly] impurity |
CN110041405A (en) * | 2019-05-07 | 2019-07-23 | 上海上药第一生化药业有限公司 | A kind of refining methd of oxytocin [5-Asp] impurity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102850441A (en) * | 2012-07-23 | 2013-01-02 | 无锡市凯利药业有限公司 | Solid-phase synthetic method of oxytocin |
CN103374054A (en) * | 2012-04-28 | 2013-10-30 | 上海第一生化药业有限公司 | One-step method based solid-phase polypeptide synthesis method |
CN103980351A (en) * | 2014-05-27 | 2014-08-13 | 上海第一生化药业有限公司 | Method for preparing vasopressin and vasopressin tannate |
CN104672308A (en) * | 2014-12-23 | 2015-06-03 | 青岛康原药业有限公司 | Method for preparing vasopressin tannate |
-
2017
- 2017-01-03 CN CN201710002364.7A patent/CN106518977B/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103374054A (en) * | 2012-04-28 | 2013-10-30 | 上海第一生化药业有限公司 | One-step method based solid-phase polypeptide synthesis method |
CN102850441A (en) * | 2012-07-23 | 2013-01-02 | 无锡市凯利药业有限公司 | Solid-phase synthetic method of oxytocin |
CN103980351A (en) * | 2014-05-27 | 2014-08-13 | 上海第一生化药业有限公司 | Method for preparing vasopressin and vasopressin tannate |
CN104672308A (en) * | 2014-12-23 | 2015-06-03 | 青岛康原药业有限公司 | Method for preparing vasopressin tannate |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110016072A (en) * | 2019-05-07 | 2019-07-16 | 上海上药第一生化药业有限公司 | A kind of refining methd of oxytocin |
CN110028556A (en) * | 2019-05-07 | 2019-07-19 | 上海上药第一生化药业有限公司 | A kind of refining methd of oxytocin [- NH2] impurity |
CN110041406A (en) * | 2019-05-07 | 2019-07-23 | 上海上药第一生化药业有限公司 | A kind of refining methd of oxytocin [+Gly] impurity |
CN110041405A (en) * | 2019-05-07 | 2019-07-23 | 上海上药第一生化药业有限公司 | A kind of refining methd of oxytocin [5-Asp] impurity |
CN110041405B (en) * | 2019-05-07 | 2021-04-13 | 上海上药第一生化药业有限公司 | Method for refining oxytocin [5-Asp ] impurity |
CN110016072B (en) * | 2019-05-07 | 2022-03-15 | 上海上药第一生化药业有限公司 | Method for refining oxytocin |
Also Published As
Publication number | Publication date |
---|---|
CN106518977B (en) | 2019-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106749539B (en) | A kind of preparation method of oxytocin deamidation impurity | |
CN106478780A (en) | A kind of preparation method of oxytocin [4 Glu] | |
CN106518977A (en) | Preparation method of oxytocin [5-Asp] | |
CN106674332B (en) | A kind of preparation method of oxytocin | |
CN106699851B (en) | A kind of preparation method of pitressin deamidation impurity | |
He et al. | Enzymatic activity and chromatographic characteristics of the cell membrane immobilized on silica surface | |
CN106749541A (en) | A kind of preparation method of pitressin [5 Asp] | |
CN106518978A (en) | Preparation method of pitressin [4-Glu,5-Asp] | |
CN103980351B (en) | The preparation method of pitressin, pitressin tannate | |
CN106518976A (en) | Preparation method of oxytocin [4-Glu, 5-Asp] | |
CN104672308A (en) | Method for preparing vasopressin tannate | |
KR100808149B1 (en) | Purified ?? | |
CN106518975B (en) | A kind of preparation method of pitressin | |
CN110016072A (en) | A kind of refining methd of oxytocin | |
CN103965291B (en) | Octreotide, the preparation method of octreotide acetate | |
CN106749540A (en) | A kind of preparation method of pitressin [4 Glu] | |
CN106749528A (en) | A kind of preparation method of Octreotide | |
CN110066319A (en) | A kind of refining methd of oxytocin acetylation impurity | |
CN110041406A (en) | A kind of refining methd of oxytocin [+Gly] impurity | |
CN110041405A (en) | A kind of refining methd of oxytocin [5-Asp] impurity | |
CN110028556A (en) | A kind of refining methd of oxytocin [- NH2] impurity | |
CN110078797A (en) | A kind of refining methd of oxytocin [4-Glu] impurity | |
CN110078796A (en) | A kind of refining methd of oxytocin [4-Glu, 5-Asp] impurity | |
CN103965296B (en) | Method for preparing angiotensin and angiotensin acetate | |
CN110016071A (en) | A kind of refining methd of pitressin [4-Glu] impurity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |